trending Market Intelligence /marketintelligence/en/news-insights/trending/kxcs_kg2mobttzx7vdh0cw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

XOMA sells rights to future royalty streams

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


XOMA sells rights to future royalty streams

HealthCare Royalty Partners II LP bought the rights to two of XOMA Corp.'s future royalty streams for $18 million up front, plus additional milestone-related payments totaling $4 million.

XOMA was eligible to receive royalty payments from each of Pfizer Inc. and Dyax Corp. after it licensed its technology to the companies.

HealthCare Royalty will pay $6.5 million in up-front payment for the Pfizer royalty payments and $11.5 million for the rights to the Dyax royalties.

HealthCare Royalty will also pay up to a further $4 million in milestone-related payments for the Pfizer royalty stream.

In other news, XOMA said it will repay $10 million it owes to Hercules Technology Growth Capital Inc. in exchange for releasing the security interest on the royalty agreements.